malformins has been researched along with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, SB; Joo, YE; Lee, WS; Myung, DS; Oh, HH; Park, D; Park, SY; Park, YL; Yu, HM | 1 |
1 other study(ies) available for malformins and benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
| Article | Year |
|---|---|
Malformin A1 treatment alters invasive and oncogenic phenotypes of human colorectal cancer cells through stimulation of the p38 signaling pathway.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasms; DNA Fragmentation; Humans; Imidazoles; MAP Kinase Signaling System; Neoplasm Invasiveness; p38 Mitogen-Activated Protein Kinases; Peptides, Cyclic; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Pyridines; Tumor Suppressor Protein p53; X-Linked Inhibitor of Apoptosis Protein | 2017 |